91插插视频,1区2区3区4区5区久久,黑人欧美插,国产 欧美 另类 制服 变态

Guangzhou Xiangxue Pharmaceutical Co., Ltd ("XPH") is a pharmaceutical company foucs on Traditional Chinese Medicine ("TCM") development and modernization as well a utilizing cutting edge biotechnology to treat cancer in the modern age. 

Founded in 1997, XPH has been listed as a public company on the Shenzhen Stock Exchange (Stock Code: 300147) since 2010, and currently has a Market Value of More than 9.7 Billion RMB.

XPH is dedicated to the health industry, specializing in the fields of modernized Traditional Chinese medicine (TCM), Chinese patent medicine, functional health care products, biomedical engineering, and T-Cell immunotherapy-based life science research. XPH integrates operation, R&D, and manufacturing, having a self-owned brand and independent innovation capacity, XPH owns most intellectual property and patents of its products. 

XPH established more than 60 subsidiaries in: Guangdong Province, Beijing, Shanxi Province, Sichuan Province, Chongqing, Anhui Province, Yunnan Province and the Ningxia Province; where XPH invested and constructed Mega-scale GMP manufacturing facilities and GAP grade Traditional Chinese Medicine (TCM) herb plantation bases all over, forming an integrated internal supply chain consisting of TCM resource development (growing TCM plants in plantations), R&D of new pharmaceuticals based on TCM, advanced TCM manufacturing plants and the development of modern logistical distribution techniques.

As a leader in the TCM Pharmaceuticals field, XPH's long-term development strategies centers on modernization of Traditional Chinese Medicine (TCM) techniques and drugs through digitalization and GMP grade R&D;  Dedicating capital, research, and industrial resources to develop cutting-edge biological technology to build the enterprise’s core competitiveness and promote its sustainable development. After years of development, XPH's many accomplishments and key technologies breakthroughs in the TCM field including: 

• The first Chinese patent medicine company in China to use fingerprinting quality control technology; 
• The first company to complete over 10,000 sets of post-market safety reasearch for Chinese patent medicine products; 
• The first company to complete double-blind, placeblo controled registered clinical studies of a Chinese patent medicine drug for the treatment of Influenza; 
• The first non-state funded TCM company to establish an overseas research center (Xiangxue Cambridge International Research Center of Chinese Medicine); 
• Registration and Approval by the British Drug Administration MHRA for our TCM product: Fragrant Snowboard Blue Root Granules.

XPH's industry leading Comprehensive TCM Resources Platform covers more than 400 TCM hearbal categories, achieving normalization, sacle, specialization, mordernization, and standardization all in one. 

In 2016, "Xiangxue Intelligent Chinese Medicine Preparation Center" was put into operation, this is the first prescription TCM preperation platform to  intergrate IOT, Internet and AI technology with TCM in China; acting as the prefect solution to the highly individualized nature of TCM medications.

XPH was founded with the mission of "Hou Sheng (厚生), Zhen Shan (臻善), Wei Xin (維新), which means cherishing life, pursuing excellence, and leading innovation. This has lead XPH to persue continuous innovation and excellence in TCM modernization, Globalization of TCM, Intergation of modern degital technology with TCM, Percision Medication, health social services, and brand development. 

Determine to forge XPH 2.0, a model to deliver high quality health products and services, XPH is dediated to the mission of helping people everywhere live healthier and happier lives.